People with acute COVID-19 who took the antiviral drug molnupiravir (Lagevrio) reported modest improvements in symptoms, less ...

Molnupiravir speeds up recovery and eases long-term symptoms, but its minimal effect on hospitalizations raises questions about its broader impact on COVID-19 care. Study: Health outcomes 3 months ...

The pill, an antiviral drug called molnupiravir, was tested against a placebo in people at high risk of developing severe disease. Of the 377 people who got the placebo, 14.1 percent, or 53 ...

Molnupiravir, an antiviral drug used to treat patients with COVID-19, appears to be driving SARS-CoV-2 to mutate and evolve, with some of these new viruses being transmitted onwards, a new study has ...

A new COVID variant, XEC, has arrived just before fall. The new variant has sprouted from the Omicron variant that developed ...

At last count, the 9.7% of people taking placebo in the trial had become seriously will with COVID-19, compared to 6.8% of the molnupiravir group. Fall in efficacy of Merck's molnupiravir puts ...

Molnupiravir is the first oral antiviral treatment for Covid to report clinical trial results. The first pill designed to treat symptomatic Covid has been approved by the UK medicines regulator.

More than 13,500 people contracted COVID-19 in Connecticut between Aug. 1 and Oct. 5, according to the most recent state data ...

New research has found that molnupiravir offers modest longer term benefits to vaccinated adults. This is the latest outcome of the NIHR funded and delivered PANORAMIC trial, led by the University of ...

New data published yesterday in Morbidity and Mortality Weekly Report (MMWR) show older adults continue to be hospitalized ...

SWEDESBORO, N.J.--(BUSINESS WIRE)--Today, Wedgewood announces the addition of molnupiravir to its formulary. Originally developed for human viral infections, including COVID-19, molnupiravir has ...

New Data to be Presented at IDWeek 2024 Reinforce Merck’s Broad and Diverse Vaccines and Infectious Disease Pipeline and ...